

FOR PUBLIC RELEASE
NZX Limited
Wellington

6th November 2024

RUA BIOSCIENCE LIMITED (NZX: RUA): NOTICE PURSUANT TO CLAUSE 20(1)(a) OF SCHEDULE 8 TO THE FINANCIAL MARKETS CONDUCT REGULATIONS 2014

1. Rua Bioscience Limited (NZX: Rua) (**Rua**) has today announced that it will undertake a pro rata 3 for 4 renounceable rights offer of fully paid ordinary shares of the same class as already quoted on the NZX Main Board operated by NZX Limited (**Rights Offer**) and may also seek to privately place any shortfall in the rights issue (**Shortfall Offer**, and together with the Rights Offer, the **Offers**). The Company is seeking to raise up to NZ\$3,069,728 in connection with the Offers.
2. Offers made under the Rights Offer will be made to investors in New Zealand in reliance upon the exclusion in clause 19 of Schedule 1 to the Financial Markets Conduct Act 2013 (**FMCA**). The Offers made under any Shortfall Offer will be made to either wholesale investors or close business associates (within the meaning of clause 3(2) or clause 4(2), as applicable, of the FMCA), or to investors in New Zealand in reliance upon the exclusion in clause 19 of Schedule 1 to the FMCA.
3. Offers under the Rights Offer are also being made to investors in Australia in reliance on the Australian Securities and Investments Commission Corporations (Foreign Rights Issues) Instrument 2015/356 or otherwise to persons to whom the Offers can be made without a full disclosure document under Chapter 6D of the Corporations Act 2001 (Cth).
4. This notice is provided pursuant to clause 20(1)(a) of Schedule 8 to the Financial Markets Conduct Regulations 2014 (**FMC Regulations**).
5. As at the date of this notice:
 - 5.1. Rua is in compliance with the continuous disclosure obligations that apply to it in relation to Rua's quoted ordinary shares;
 - 5.2. Rua is in compliance with its "financial reporting obligations" (as defined in clause 20(5) of Schedule 8 to the FMC Regulations); and
 - 5.3. there is no information that is "excluded information" (as defined in clause 20(5) of Schedule 8 to the FMC Regulations) in respect of Rua.
6. The Offers are not expected to have any effect on the "control" (as defined in clause 48 of Schedule 1 to the FMCA) of Rua.

END

Authorised by the Board of Rua Bioscience Limited.

For further information please contact:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154